Aztiq's shareholders are comprised of individual investors as well as large international investment funds.

The Fund’s largest assets are pharmaceutical companies Alvogen, a privately owned global pharmaceutical company that develops, manufactures and markets generic, brand, over-the-counter and biosimilar products for patients around the world; Alvotech, a fully integrated biopharmaceutical company focused exclusively on developing and bringing to market biosimilar medicines; and the real estate company Saemundur. Additionally, Aztiq is a major shareholder in Þorpið (reads Thorpid) – an ecological community development project, in partnership with the City of Reykjavik.

Currently, Aztiq is in the process of building a high-tech biologics R&D and manufacturing facility in the University of Iceland Science Park Reykjavik, next to Alvotech's headquarters. The Science Park was established to help advance collaboration and innovation between companies, research institutes and universities, and to create facilities for entrepreneurs. Alvotech established its headquarters facility there and from its inauguration has collaborated with university students and faculty research and training in biologic medicines. Aztiq Fund is proud to be continuing and extending this tradition, and he current project will double the size of the Fund’s pharmaceutical facilities in Iceland.